Different Therapeutic Options Required for Subtypes in Mantle Cell Lymphoma
June 25th 2019Ezzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma. MCL is a spectrum of diseases that should be treated differently, he says.
Watch
Discussing Targeted Treatment With PARP Inhibitors for BRCA-Mutant Patients Across Tumor Types
June 25th 2019Susan Friedman, executive director and founder, FORCE, a non-profit organization supporting education, advocacy, and research around breast and ovarian cancer, explains the relevance of PARP inhibitors and the recent developments in oncology research that may improve cancer treatment for patients with genetic mutations.
Watch
Triplet Regimen Improves Responses in BRAF V600E+ Metastatic CRC
June 24th 2019Tanios Bekaii-Saab, MD, discusses the results from the phase III BEACON CRC study; investigators evaluated the efficacy and safety of triplet encorafenib, binimetinib, and cetuximab in patients with BRAF V600E–mutant metastatic colorectal cancer who previously received up to 2 lines of prior therapy.
Watch